SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff following reports of a major Binance security breach is the main pressure on Strategy, whose shares traders view as closely tied to BTC. The community is split between buying the dip and warning that crypto-security concerns, alongside Strategys revenue miss and CFO transition, could weigh further on the stock.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a fresh 52-week high ahead of the upcoming Q3 report has traders focused on BRIUMVIs sales ramp and managements outlook; some point to earnings expectations, while others speculate about an unconfirmed buyout and short covering.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could fall after the first quarter of 2027 has fueled concerns about CorMedixs pricing and revenue, alongside a sharp selloff. Traders disagree on how much weight to give DaVitas preliminary outlook, with some pointing to CMSs published reimbursement estimate while others see ongoing pressure ahead.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 77,177.65528711 USD and is down -1.08 over the last 24 hours. It is currently trading on 12773 active market(s) with $46,266,908,298.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

A reported major Binance security breach is driving concern about exchange safety, possible withdrawals and selling pressure across crypto. Traders are divided between expecting further downside from shaken confidence and viewing Bitcoins relative resilience as a buying opportunity, arguing the breach affects the exchange rather than Bitcoins network.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Energy-sector strength and concern over oil-supply disruptions tied to Middle East tensionsespecially risks to shipping and refiningdominate the discussion around XLE. Traders point to the rally and energys relative strength as bullish, while others warn that diplomatic progress, profit-taking, or an overextended move could weigh on the fund.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Attention is focused on upcoming Q3 results and the Casgevy sales update, with traders debating whether rising patient starts and treatment-center expansion will translate into stronger collaboration revenue. The upcoming CTX310 clinical presentation is another key catalyst; sentiment is mixed between anticipation of data-driven progress and concern about the stocks decline and CFO transition.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

Energy Transfers strong quarterly results and outlook are fueling discussion of its potential to benefit from rising natural-gas demand for AI data centers and other power customers. Many traders are bullish on that growth and the distribution, while others are frustrated that the unit price has not responded more strongly.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

XLK is drawing attention amid a sharp technology-sector selloff, with traders citing broad technical breakdowns and weakness in semiconductors and other tech groups. The conversation is mostly bearish, though some see the pullback as a potential buying opportunity or expect a bounce; confirmation of support remains a key debate.

Amp (AMP) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Amp has a current supply of 99,720,267,351.28921674 with 89,781,193,103.18022 in circulation. The last known price of Amp is 0.0006528 USD and is up 0.85 over the last 24 hours. It is currently trading on 193 active market(s) with $5,174,420.89 traded over the last 24 hours. More information can be found at https://amp.xyz.

AMP Token

A sharp AMP rally and volume spike have traders speculating about renewed interest in the Flexa/Anvil payment-infrastructure thesis and AMPs collateral role. Others say there is no confirmed new catalyst and warn the move may be another short-lived pump.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbases post-earnings selloff is drawing attention as traders weigh weak underlying crypto-trading activity and a revenue shortfall against headline profitability, much of which they attribute to gains on crypto holdings. A Bitcoin slide and Binance hack concerns are adding pressure, though some traders view the decline as an overreaction or buying opportunity.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates

Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of +75.00% and +10.19%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2026 financial results and business updates on...

VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes

Equity

On Wednesday, Verastem said that in its ongoing early-stage TARGET-D 101 trial, VS-7375 produced a 50% confirmed overall response rate in second-line metastatic pancreatic ductal adenocarcinoma at the 900 mg daily dose. 


Companies Entering High-Stakes Market Moments

The following developments are worth watching, with Dermata Therapeutics (NASDAQ:DRMA), Verastem (NASDAQ:VSTM), NeOnc Technologies Holdings (NASDAQ:NTHI), Netcapital (NASDAQ:NCPL), Iambic Therapeutics (NASDAQ:IAM) and Estrella Immunopharma (NASDAQ:ESLA) advancing distinct strategies.

Wall Street’s Next Movers

The market is serving up a powerful mix of movers, including Alaunos Therapeutics (NASDAQ:TCRT) completed a major acquisition backed by a $350 million private placement, while NeOnc Technologies Holdings (NASDAQ:NTHI) is preparing for an important FDA discussion. Verastem Oncology (NASDAQ:VSTM) reported fresh cancer-drug results alongside a major financing and leadership transition, and Liquidia (NASDAQ:LQDA) resolved a prolonged legal battle over its pulmonary-hypertension treatment. Bending Spoons (NASDAQ:BSP) is attracting another major investment from Berkshire Hathaway.

Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers

Verastem Oncology reports promising VS-7375 response rates in pancreatic, colorectal, and lung cancers, with a Phase 3 trial planned for 2026.read more...

Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday

U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire's $330M investment. Liquidia and Verastem also posted strong gains.read more...

Verastem Has Positive Early Cancer Data And $250M In New Funding: What VSTM Investors Need To Know 

Verastem reported positive results from its ongoing Phase 1/2 trial involving patients with advanced cancers carrying the KRAS G12D mutation.


Verastem Oncology Prices $250 Mln Stock, Warrant Offering; Pre-market Shares Up

(RTTNews) - Biopharmaceutical company Verastem Oncology (VSTM), announced on Wednesday that it has priced an underwritten offering of 30.94 million shares at $8 each and pre-funded warrants for 0.31 million shares at $7.9999 each, raising about $250 million...

Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 30,937,500 shares of its...

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Alliance Global on Thursday raised its price target on VSTM to $22 from $18 and maintained a Buy rating.</li><li>RBC Capital analyst Leonid Timashev said that while VS-7375 tolerability is not as favorable as Revolution Medicines’ experimental drug Zoldonrasib, the overall profile remains acceptable.&nbsp;</li><li>BTIG said VS-7375 could rival Revolution Medicines’ approved drug Daraxonrasib in second-line metastatic pancreatic disease.</li></ul> Shares of Verastem Oncology (VSTM) jumped 20% on Thursday, clocking its best day since Nov. 2025, as analysts lifted price targets following a positive update on the company’s experimental drug VS-7375 in second-line metastatic pancreatic ductal adenocarcinoma.On Wednesday, Verastem said that in its ongoing early-stage TARGET-D 101 trial, VS-7375 produced a 50% confirmed overall response rate in second-line metastatic pancreatic ductal adenocarcinoma at the 900 mg daily dose, along with responses in lung and colorectal cancers and a manageable safety profile dominated by low-grade gastrointestinal side effectsVerastem also added that the company has aligned with the U.S. Food and Drug Administration on a late-stage path in first-line metastatic pancreatic cancer using chemotherapy-free regimens, with the study expected to open by year-end.<h2 class="st-heading-2">Wall Street Weighs In On VSTM</h2>Alliance Global on Thursday subsequently raised its price target to $22 from $18 and maintained a Buy rating, describing the updated TARGET-D 101 data as showing a highly tolerable safety profile and efficacy that is in line with or better than other drugs in the same class and in development, potentially best-in-class.RBC Capital analyst Leonid Timashev increased the target to $19 from $14 while keeping an Outperform rating, calling the drug clearly active with hints of best-in-class efficacy in pancreatic ductal adenocarcinoma. He noted that while tolerability is not as favorable as one competitor, Revolution Medicines’ experimental drug Zoldonrasib, the overall profile remains acceptable.BTIG raised its target to $24 from $18 and kept a Buy rating, saying the detailed update across second-line pancreatic cancer, second-line non-small cell lung cancer, and third-line colorectal cancer points to class-leading efficacy that could rival Revolution Medicines’ approved drug Daraxonrasib in second-line metastatic pancreatic disease.Jefferies analyst Faisal Khurshid raised the price target to $13 from $11 and maintained a Buy rating. Aligning on a favorable late-stage trial path, he added, positions Verastem only about seven months behind competitors Revolution Medicines and Incyte in the race to develop drugs within the same class.<h2 class="st-heading-2">CEO Change And Capital Raising</h2>Verastem on Wednesday also priced a $250 million offering of common stock and pre-funded warrants at $8 per share to support VS-7375 development and general purposes, expected to close around October 15.The company further announced a planned CEO transition, with longtime executive Daniel Paterson retiring effective January 1, 2027, and board member Michael P. Bailey succeeding him.<h2 class="st-heading-2">How Did VSTM Retail Traders React?</h2>On Stocktwits, retail sentiment around VSTM stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.“The more I watch it, the more constructive it looks,” a Stocktwits user wrote about the stock.<stembedurl>https://stocktwits.com/topstockalerts/message/666627602</stembedurl>Another user drew a parallel between VSTM’s current rally and Iovance Biotherapeutics Inc (IOVA) stock’s rally last month, which lasted for several days.<stembedurl>https://stocktwits.com/Always_neutral/message/666623781</stembedurl><a class="mention" data-mention="$VSTM" data-symbol-id="VSTM" href="https://stocktwits.com/symbol/VSTM" target="_blank">VSTM stock</a> has gained 2o% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mrna-stock-hits-fresh-52-week-highs-as-goldman-raises-target-ahead-of-melanoma-data/cZxh3NsRBrS">MRNA Stock Hits Fresh 52-Week Highs As Goldman Raises Target Ahead Of Melanoma Data</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Verastem Oncology logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

On Wednesday, Verastem said that in its ongoing early-stage TARGET-D 101 trial, VS-7375 produced a 50% confirmed overall response rate in second-line metastatic pancreatic ductal adenocarcinoma at the 900 mg daily dose. 

Incyte Corp.

Revolution Medicines Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$9.75
Prev Close	$9.66
Open	$9.63
Dividend Yield	0.00%
50-Day Moving Average	$8.16
Beta	1.24
Avg. Volume	2.47M
PE Ratio	-3.96

52-Week High	$10.82
52-Week Low	$3.43
Market Capitalization	$1.18B
EPS (Annual)	-$3.02
Price to Book	17.65
Revenue Per Employee	$303,078.43

Feed

News

Sentiment

Earnings

Fundamentals

Info

VSTM Fundamentals